Literature DB >> 29611104

Fixed-dose 4-factor prothrombin complex concentrate: we don't know where we're going if we don't know how to get there.

Scott T Hall1, Kyle C Molina2.   

Abstract

4-Factor Prothrombin Complex Concentrate (4F-PCC) is the standard-of-care intervention in patients with major bleeding taking oral vitamin K antagonists. Despite growing clinical experience with 4-FPCC, the optimal dosing strategy remains unclear. In balancing efficacy, safety, and cost of this treatment, many institutions have adopted a low, fixed-dose regimen, with average doses lower than that in the package insert. The fixed-dose 4F-PCC strategy is supported by the available observational studies and case reports; however, the current body of literature is highly heterogenous. The purpose of this narrative review is to address the advantages and shortcomings with clinical use of fixed-dose 4F-PCC, as well as limitations of the available literature. The heterogeneity of the current literature should guide future studies to support or refute this potentially life-saving intervention.

Entities:  

Keywords:  Bleed; Fixed-dose; Prothrombin complex concentrate; Reversal; Warfarin

Mesh:

Substances:

Year:  2018        PMID: 29611104     DOI: 10.1007/s11239-018-1653-y

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  22 in total

1.  Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy.

Authors:  N Khorsand; N J G M Veeger; M Muller; J W P M Overdiek; W Huisman; R M van Hest; K Meijer
Journal:  Transfus Med       Date:  2010-11-15       Impact factor: 2.019

2.  Prothrombin complex concentrate for emergent reversal of warfarin: an international survey of hospital protocols.

Authors:  J Gorlin; S Kinney; M K Fung; A Tinmouth
Journal:  Vox Sang       Date:  2017-06-21       Impact factor: 2.144

3.  Evaluation of fixed dose 4-factor prothrombin complex concentrate for emergent warfarin reversal.

Authors:  Lauren Klein; Jessica Peters; James Miner; Jed Gorlin
Journal:  Am J Emerg Med       Date:  2015-05-29       Impact factor: 2.469

4.  Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial.

Authors:  Lonneke van Aart; Heleen W Eijkhout; Jan S Kamphuis; Marco Dam; Marinus Eeftinck Schattenkerk; Teunis J Schouten; Ben Ploeger; Paul F W Strengers
Journal:  Thromb Res       Date:  2005-09-21       Impact factor: 3.944

Review 5.  2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.

Authors:  Gordon F Tomaselli; Kenneth W Mahaffey; Adam Cuker; Paul P Dobesh; John U Doherty; John W Eikelboom; Roberta Florido; William Hucker; Roxana Mehran; Steven R Messé; Charles V Pollack; Fatima Rodriguez; Ravindra Sarode; Deborah Siegal; Barbara S Wiggins
Journal:  J Am Coll Cardiol       Date:  2017-12-01       Impact factor: 24.094

Review 6.  Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine.

Authors:  Jennifer A Frontera; John J Lewin; Alejandro A Rabinstein; Imo P Aisiku; Anne W Alexandrov; Aaron M Cook; Gregory J del Zoppo; Monisha A Kumar; Ellinor I B Peerschke; Michael F Stiefel; Jeanne S Teitelbaum; Katja E Wartenberg; Cindy L Zerfoss
Journal:  Neurocrit Care       Date:  2016-02       Impact factor: 3.210

7.  Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis.

Authors:  Francesco Dentali; Chiara Marchesi; Matteo Giorgi Pierfranceschi; Mark Crowther; David Garcia; Elaine Hylek; Daniel M Witt; Nathan P Clark; Alessandro Squizzato; Davide Imberti; Walter Ageno
Journal:  Thromb Haemost       Date:  2011-07-28       Impact factor: 5.249

8.  An observational, prospective, two-cohort comparison of a fixed versus variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergencies.

Authors:  Nakisa Khorsand; Nic J G M Veeger; Reinier M van Hest; Paula F Ypma; Jeroen Heidt; Karina Meijer
Journal:  Haematologica       Date:  2012-04-04       Impact factor: 9.941

Review 9.  A systematic review of prothrombin complex concentrate dosing strategies to reverse vitamin K antagonist therapy.

Authors:  Nakisa Khorsand; Hilde A M Kooistra; Reinier M van Hest; Nic J G M Veeger; Karina Meijer
Journal:  Thromb Res       Date:  2014-11-22       Impact factor: 3.944

10.  Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.

Authors:  Ravi Sarode; Truman J Milling; Majed A Refaai; Antoinette Mangione; Astrid Schneider; Billie L Durn; Joshua N Goldstein
Journal:  Circulation       Date:  2013-08-09       Impact factor: 29.690

View more
  1 in total

Review 1.  Collaborative Management Strategies for Drug Shortages in Neurocritical Care.

Authors:  Sarah L Clark; Kimberly Levasseur-Franklin; Mehrnaz Pajoumand; Megan Barra; Michael Armahizer; Deepa V Patel; Katleen Wyatt Chester; Andrea P Tully
Journal:  Neurocrit Care       Date:  2020-02       Impact factor: 3.210

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.